If you’d like to see something here about medicines which is currently missing, please use the “Contact us” link at the top of the page or e-mail SWYAPC@greaterhuddersfieldccg.nhs.uk.
Preparations for dry skin (emollients)
West Yorkshire Fire & Rescue Service – Essential Information for Health Care Professionals
Following local deaths, West Yorkshire Fire & Rescue Service has produced a YouTube Video for healthcare professionals about emollients, which can increase the risk of a fire developing. Please watch it and discuss it within your team.
They would like you to consider:
- All of these products are safe to use but they all increase the flammability of fabrics. The problem arises when an ignition source (primarily smoking materials such as matches and some lighters) is introduced and the bedding the person is lying on, the chair they are sitting on, the clothes or dressings they are wearing are accidentally set on fire.
- Changing prescriptions to lower paraffin containing products will not reduce the fire risk.
- Preliminary scientific research is also showing that non-paraffin alternatives will also not reduce the fire risk.
- The potential fire risk therefore applies to all emollients.
They strongly recommend:
- In line with various Coroner’s reports to Prevent Future Deaths that all those who apply these products should give a verbal warning about these fire risks to their patients, or people they are caring for. This is in addition to the warnings that will appear on these products.
- If anyone has concerns that someone is displaying high risk behaviours around fire and the use of emollients, that a referral is made to us (or your local fire service)so that we can try to mitigate the risk through information, advice and appropriate interventions.
Medicines and Healthcare products Regulatory Agency (MHRA)
The MHRA has also highlighted the risks in a press release.
It was previously thought the risk occurred with emollients which contain more than 50% paraffins. However, evidence now points to a risk with emollients which contain lower levels of paraffin and with paraffin-free emollients. This advice therefore applies to all emollients whether they contain paraffin or not.
It is important people caring for someone who uses an emollient, are aware of the potential fire risks and take appropriate action.
Further details are available here Press Release MHRA 181218
BBC News Health has again highlighted the dangers of using preparations for dry skin whilst smoking or using naked flames.
Form to complete and fax to GP if an older resident has a suspected urinary tract infection:
Management of UTIs in nursing homes form (minor changes to website addresses Sept 18)
See also the Antimicrobial Guidelines for Primary Care .
Public Health England has issued ‘Guidelines on the management of outbreaks of influenza-like illness in care homes’ Influenza-like_illness_in_care_home_2018
Public Health England has issued guidance about infection control in residents with Candida auris
The wound management formulary has been developed by the Joint Wound Management Formulary Group.
Please click the link to navigate to the relevant sections of the wound formulary.
Newsletter about concern regarding high strength insulin:
A patient safety alert has been issued about the risk of severe harm and death resulting from withdrawing insulin from pen devices. This notes that
56 incidents have been reported which were associated with withdrawing insulin from insulin pens or refill cartridges.
Extracting insulin from pen devices or cartridges is dangerous and should not happen.
Managing Medicines in Care Homes
From NICE: Guideline on Managing Medicines in Care Homes.
Quality standard – Medicines Management in Care Homes.
Flow chart – Managing Medicines in Care Homes.
Some things to think about when considering covert administration of medicine
Some things to consider when crushing tablets or opening capsules.
Some useful websites
Advice on diamorphine and Intrasite gel
The CDAO are aware of the unlicensed use of Intrasite gel and diamorphine injection in certain settings.
The decision to use this would be a clinical judgement for the individual prescriber.
In all cases, if this is the chosen treatment, both the person administering the treatment, and the patient, must be aware of its unlicensed status. There must also be a full audit trail for the use of the Diamorphine (including destruction details of any part ampoules that may have been discarded)
Regarding treatment suitability and evidence please contact the Yorkshire Cancer Network